Diligence memo · auto-generated · as of July 2, 2026

Telos Biotech Inc.

Telos Biotech Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Telos Biotech Inc. operates in Biotechnology, based in Dallas.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Telos Biotech Inc. has raised $1.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $725K on 2025-12-01.

Most recent recorded round closed around 2025-12-01.

Valuation (modeled)modeled

Provath models Telos Biotech Inc. at approximately $1.4M (range $387K–$3.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.45× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (145% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 71 months.

Last raise 7 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 23% of Biotechnology peers (4293 compared).

Modeled value ranks above 4% of those peers.

Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.